EG25009A - Aniline derived ligands for the thyroid receptor. - Google Patents

Aniline derived ligands for the thyroid receptor.

Info

Publication number
EG25009A
EG25009A EG20010132A EG20010132A EG25009A EG 25009 A EG25009 A EG 25009A EG 20010132 A EG20010132 A EG 20010132A EG 20010132 A EG20010132 A EG 20010132A EG 25009 A EG25009 A EG 25009A
Authority
EG
Egypt
Prior art keywords
thyroid receptor
derived ligands
aniline derived
aniline
ligands
Prior art date
Application number
EG20010132A
Other languages
English (en)
Inventor
Todd Jason Friends
Dennis E Ryono
Minsheng Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG25009A publication Critical patent/EG25009A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EG20010132A 2000-02-17 2001-02-14 Aniline derived ligands for the thyroid receptor. EG25009A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18322300P 2000-02-17 2000-02-17

Publications (1)

Publication Number Publication Date
EG25009A true EG25009A (en) 2011-05-16

Family

ID=22671959

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010132A EG25009A (en) 2000-02-17 2001-02-14 Aniline derived ligands for the thyroid receptor.

Country Status (30)

Country Link
US (2) US6800605B1 (fr)
EP (1) EP1257526B1 (fr)
JP (1) JP4629294B2 (fr)
KR (1) KR100740383B1 (fr)
CN (1) CN1216857C (fr)
AR (1) AR031094A1 (fr)
AT (1) ATE295348T1 (fr)
AU (2) AU2001230929B2 (fr)
BR (1) BR0108134A (fr)
CA (1) CA2400486C (fr)
CO (1) CO5271672A1 (fr)
CZ (1) CZ20022771A3 (fr)
DE (1) DE60110753T2 (fr)
DK (1) DK1257526T3 (fr)
EG (1) EG25009A (fr)
ES (1) ES2242723T3 (fr)
HK (1) HK1047925B (fr)
HU (1) HUP0301777A3 (fr)
IL (2) IL150449A0 (fr)
MX (1) MXPA02007929A (fr)
MY (1) MY124534A (fr)
NO (1) NO329639B1 (fr)
NZ (1) NZ520023A (fr)
PE (1) PE20020767A1 (fr)
PL (1) PL201790B1 (fr)
PT (1) PT1257526E (fr)
RU (1) RU2260586C2 (fr)
UY (1) UY26581A1 (fr)
WO (1) WO2001060784A1 (fr)
ZA (1) ZA200206072B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DE10131462A1 (de) * 2001-06-29 2003-01-09 Bayer Ag Phenol-Derivate
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
WO2003042162A1 (fr) * 2001-11-17 2003-05-22 Neurosearch A/S Promedicaments d'antidepresseurs et utilisation associee dans le traitement de la depression
GB0208384D0 (en) * 2002-04-11 2002-05-22 Karobio Ab Novel compounds
US20040176425A1 (en) * 2003-01-24 2004-09-09 Washburn William N. Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
DK1660090T3 (da) * 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
GB0606201D0 (en) 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
US8922530B2 (en) * 2010-01-06 2014-12-30 Apple Inc. Communicating stylus
EP2609910A1 (fr) 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Formulations d'eprotirome
EP2695611B1 (fr) * 2012-08-06 2014-10-01 Dr. August Wolff GmbH & Co. KG Arzneimittel Eprotirome pour l'utilisation dans la prévention et/ou le traitement de troubles de cheveux et compositions correspondantes
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
DK3457851T3 (da) * 2016-05-18 2021-09-20 Univ Oregon Health & Science Derivater af sobetirom
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (fr) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions pour le traitement de la fibrose et de l'inflammation
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
CN113474335B (zh) 2019-02-21 2024-12-03 南京瑞捷医药科技有限公司 化合物及其作为甲状腺激素受体激动剂的用途
WO2020180624A1 (fr) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Nouveaux thyromimétiques
US12466781B2 (en) 2019-11-29 2025-11-11 Autobahn Therapeutics, Inc. Thyromimetics
US20230257367A1 (en) 2020-06-02 2023-08-17 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone beta receptor agonist
US12590072B2 (en) 2020-06-17 2026-03-31 Autobahn Therapeutics, Inc. Thyromimetics
WO2021257851A1 (fr) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimétiques
WO2023177667A1 (fr) * 2022-03-16 2023-09-21 Brii Biosciences, Inc. Agonistes du récepteur des hormones thyroïdiennes
WO2025019825A2 (fr) * 2023-07-20 2025-01-23 Brii Biosciences, Inc. Dérivés de 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phénoxy)acétamide substitués

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1078582B (de) * 1958-10-29 1960-03-31 Hoechst Ag Verfahren zur Herstellung substituierter Thyropropionsaeuren
JPS6061747A (ja) * 1983-09-16 1985-04-09 Konishiroku Photo Ind Co Ltd 熱現像感光材料
DE69314718T2 (de) 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
HK1044532A1 (zh) 1999-03-01 2002-10-25 辉瑞产品公司 用作甲状腺受体配体的草氨酸及衍生物
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
ES2240017T3 (es) 1999-09-30 2005-10-16 Pfizer Products Inc. Derivados de 6-azauracilo como ligandos de receptores tiroideos.
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DZ3276A1 (fr) * 2000-03-31 2001-10-04 Pfizer Prod Inc Acides malonamiques et leurs derives, utiles comme ligands de recepteurs thyroidiens
WO2001085670A1 (fr) * 2000-05-12 2001-11-15 Kissei Pharmaceutical Co., Ltd. Derives d'acide malonanilique, compositions medicinales les contenant et leur utilisation
WO2002094319A1 (fr) * 2001-05-18 2002-11-28 Kissei Pharmaceutical Co., Ltd. Agents de prevention du cancer du foie ou empechant la recurrence de ce dernier
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor

Also Published As

Publication number Publication date
AU2001230929B2 (en) 2004-09-23
EP1257526A1 (fr) 2002-11-20
NO329639B1 (no) 2010-11-22
HK1047925A1 (en) 2003-03-14
HUP0301777A2 (hu) 2003-09-29
ES2242723T3 (es) 2005-11-16
JP2004500382A (ja) 2004-01-08
AR031094A1 (es) 2003-09-10
NZ520023A (en) 2004-05-28
DE60110753T2 (de) 2006-02-23
UY26581A1 (es) 2001-09-28
CA2400486C (fr) 2011-01-11
US7109164B2 (en) 2006-09-19
IL150449A0 (en) 2002-12-01
DK1257526T3 (da) 2005-09-12
NO20023895L (no) 2002-10-16
US6800605B1 (en) 2004-10-05
MXPA02007929A (es) 2003-02-10
CZ20022771A3 (cs) 2003-09-17
KR100740383B1 (ko) 2007-07-16
ATE295348T1 (de) 2005-05-15
HK1047925B (en) 2005-11-11
DE60110753D1 (de) 2005-06-16
CA2400486A1 (fr) 2001-08-23
MY124534A (en) 2006-06-30
ZA200206072B (en) 2004-02-11
NO20023895D0 (no) 2002-08-16
AU3092901A (en) 2001-08-27
IL150449A (en) 2008-03-20
PE20020767A1 (es) 2002-08-17
US20050032890A1 (en) 2005-02-10
EP1257526B1 (fr) 2005-05-11
HUP0301777A3 (en) 2010-09-28
PL366149A1 (en) 2005-01-24
WO2001060784A1 (fr) 2001-08-23
PL201790B1 (pl) 2009-05-29
CO5271672A1 (es) 2003-04-30
RU2260586C2 (ru) 2005-09-20
JP4629294B2 (ja) 2011-02-09
KR20020075799A (ko) 2002-10-05
CN1418185A (zh) 2003-05-14
CN1216857C (zh) 2005-08-31
RU2002123349A (ru) 2004-01-10
BR0108134A (pt) 2003-09-30
PT1257526E (pt) 2005-09-30

Similar Documents

Publication Publication Date Title
EG25009A (en) Aniline derived ligands for the thyroid receptor.
HUP0104666A3 (en) Thyroid receptor ligands
MXPA03002691A (es) Ligandos de receptor de melanocortina.
MXPA03009791A (es) Ligandos para el receptor de melanocortina.
AU2003225305A8 (en) Pyridine-based thyroid receptor ligands
ZA200107411B (en) Melanocortin receptor ligands.
ZA200203450B (en) beta2-adrenergic receptor agonists.
MXPA03007078A (es) Ligandos del receptor de canabinoide.
ZA200206768B (en) Aryl fused azapolycyclic compounds.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
MXPA03004527A (es) Compuestos antagonicos lfa-1.
ZA200200477B (en) 2-pyrazolin-5-ones.
ZA200202537B (en) Pour-on-formulations.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
ZA200108968B (en) New compounds.
IL157031A0 (en) Thyroid receptor ligands
ZA992596B (en) Azabicyclic 5HT1 receptor ligands.
ZA200106875B (en) Trace elements.
ZA200200784B (en) Calcilytic compounds.
ZA200204581B (en) Nitro-sulfobenzamides.
ZA200108129B (en) Histidine protein-phosphatase.
ZA200107421B (en) Complexing agents.
ZA200005361B (en) Positioning arrangement.
ZA986876B (en) 1-Phenyl-4-benzylpiperazines; dopamine receptor subtype specific ligands.
ZA200004838B (en) Electromembrane.